Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A company-sponsored clinical study of off-the-shelf K-NK003 cells in patients with relapsed/refractory acute myeloid leukemia (R/R AML)

Next Previous
Trial Profile

A company-sponsored clinical study of off-the-shelf K-NK003 cells in patients with relapsed/refractory acute myeloid leukemia (R/R AML)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs K NK003 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Kiadis Pharma

Most Recent Events

  • 28 Feb 2020 New trial record
  • 26 Feb 2020 According to an Kiadis Pharma media release, the Ohio State University and the company plan to work together to initiate a company sponsored trial with off-the-shelf K-NK003 cells expanded with particle production platform (PM21) in patients with relapsed/refractory acute myeloid leukemia later in 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top